Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 4/20 | 0.37 |
| ▸ | WDR5 | P61964 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.34 |
| ▸ | STS | P08842 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16783751 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL41973 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL2147759 | 0.93 | HSD11B1 (0.37) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL12537944 | 0.88 | HSD11B1 (0.38) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL3144755 | 0.87 | CXCR3 (0.41) | CHRM1 | |
| SCHEMBL2450689 | 0.86 | DRD2 (0.31) | — | |
| SCHEMBL15437682 | 0.85 | HSD11B1 (0.41) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL28946 | 0.85 | HSD11B1 (0.34) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL2147628 | 0.85 | HSD11B1 (0.34) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL15437681 | 0.85 | HSD11B1 (0.41) | CHRM2CHRM1CHRM3HSD11B1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250090524-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-03-20 | — | — | US | disclosed |
| CN-118984829-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-115087640-B | Pyrimidine compound substituted by bridged heterocyclic group, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-11-05 | — | — | CN | disclosed |
| EP-4430048-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-3630116-B1 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240109890-A1 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | THE NAT INSTITUTES OF PHARMACEUTICAL R&D CO LTD (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4279485-A1 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2006113458-A1 | HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-19 | — | — | US | disclosed |
| US-20060199799-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-07 | — | — | US | disclosed |
| US-20060025402-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-02-02 | — | — | US | disclosed |
| US-6951849-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6809199-B2 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES | MERCK & CO., INC. | 2004-10-26 | — | — | US | disclosed |
| WO-2004089942-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2002058695-A9 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2003-09-12 | — | — | WO | disclosed |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109890-A1 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | TYK2, JAK1, JAK2 | CHRM2 4704/4885CHRM1 4440/4885CHRM3 4556/4885 |
| US-20250090524-A1 | BTK INHIBITORS | BTK, SYK, LYN | CHRM2 4879/4885CHRM1 4875/4885CHRM3 4856/4885 |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MAPK1, MAPK7, MAPKAPK2 | CHRM2 4850/4885CHRM1 4813/4885CHRM3 4837/4885 |
| US-20060025402-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | CHRM2 3/4885CHRM1 2/4885CHRM3 4/4885 |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM5, CHRM1 | CHRM2 5/4885CHRM1 3/4885CHRM3 4/4885 |
| US-20060199799-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | CHRM2 3/4885CHRM1 2/4885CHRM3 4/4885 |
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | PRMT1, PRMT3, PRMT8 | CHRM2 4402/4885CHRM1 3912/4885CHRM3 4401/4885 |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | CHRM2 4155/4885CHRM1 4279/4885CHRM3 3445/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | CHRM2 4796/4885CHRM1 4808/4885CHRM3 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.